SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: CuttingEdge Bio who wrote (2785)11/7/2019 12:17:28 PM
From: Miljenko Zuanic  Respond to of 3557
 
My memory is running short (I am older not younger), was that trial modified in part-1 after split?
Primary objective was mPFS, and than broken into 2 parts, now for part1 it is ORR!
clinicaltrials.gov

Is it possible that mPFS (by IRC) still can be secondary for Part-1? What is REGN afraid? Or, they already have data that it failed...or there is no big difference????